At a glance
ClinicalIndex Comparison RecordN/ACompleted· 19 enrolled
Drug / intervention
HALOdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers
In Brief
A clinical study evaluating HALO for Nicotine Dependence, Other Tobacco Product and 3 related conditions. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This study will test feasibility, in smokers with lung, head \& neck, and bladder cancers, that examines the effect of e-cigarette substitution, on measures of smoking-related toxicity and medical outcomes. The aim of the study is to determine the appeal of e-cigarettes compared to regular combustible cigarettes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNicotine Dependence, Other Tobacco Product, Bladder Cancer, Lung Cancer, Cancer of Head and Neck
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartJun 2016
Primary CompletionMay 2018
TodayJul 2026
First PostedJan 6, 2016
Enrollment StartJun 1, 2016
Primary CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.5 years ago
Interventions
HALOdevice
HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.